Purpose: To evaluate the short- and long-term effects of selective serotonin reuptake inhibitors (SSRIs) on intraocular pressure (IOP) and anterior segment parameters in open angle eyes. Materials and methods: This cross-sectional study included 325 eyes of 166 subjects. Subjects were divided into three groups: Group 1 included 116 eyes of 58 patients receiving SSRIs for 1 week–6 months, Group 2 included 102 eyes of 53 patients receiving SSRIs for longer than 6 months and Group 3 included 107 eyes of 55 healthy subjects not receiving any drugs. All of the patients receiving SSRIs were diagnosed as major depressive disorder. All groups were chosen to be similar in terms of age and gender. All patients underwent a detailed ophthalmologic examination including IOP measurement by Goldmann applanation tonometer and gonioscopy. Anterior segment parameters including pupil diameter (PD), central corneal thickness (CCT), anterior chamber depth (ACD), anterior chamber volume (ACV), and anterior chamber angle (ACA) were assessed by a Scheimpflug system. Results: Pupil diameter was significantly larger in patients receiving SSRIs for <6 months and ≥6 months than the control subjects (3.53 ± 0.71 mm, 3.48 ± 0.60 mm versus 3.11 ± 0.72 mm, p < 0.05) but this effect was independent from the duration of SSRI treatment. IOP was significantly lower in patients receiving SSRIs for <6 months and ≥6 months than the control group (16.04 ± 2.17 mm Hg, 16.11 ± 2.13 mm Hg versus 17.34 ± 2.15 mmHg, p < 0.05), but there were no statistically significant differences between the patients receiving SSRIs for <6 months and ≥6 months. There were no statistically significant differences between the patient and the control group in values of CCT, ACD, ACV and ACA. The ACAs were measured between 25° and 55° with Scheimpflug system and also classified as grade 3–4 (Shaffer system) by gonioscopy. Conclusions: Selective serotonin reuptake inhibitors cause mydriasis which is persistent during the treatment. In depression patients with open angle eyes, short- and long-term use of SSRIs leads to decrease in IOP.
Juxtapapillary retinal capillary hemangiomas (JRCHs) are benign vascular tumors located on or adjacent to the optic nerve head. A 19-year-old girl presented with epiretinal membrane (ERM) associated with an elevated and round vascular tumoral mass located in the juxtapapillary region of her left eye. She was subsequently diagnosed with isolated JRCH. A combined approach with laser photocoagulation and intravitreal bevacizumab injection was used to facilitate shrinkage of the tumor preoperatively and pars plana vitrectomy was used to remove the tumor and ERM. A small remnant of tumoral mass remained intact and did not show any growth for 7 years.
1 May 2018 in Journal of Ocular Pharmacology and Therapeutics
Purpose: To evaluate anterior segment parameters and intraocular pressure (IOP) modifications in patients using serotonin noradrenaline reuptake inhibitors (SNRIs) due to major depressive disorder. Methods: This cross-sectional study included 170 eyes of 85 subjects. All subjects were divided into three groups: group 1 included 44 healthy control subjects, group 2 included 22 patients receiving antidepressants for 1 week to 6 months, and group 3 included 19 patients receiving antidepressants for >6 months. All subjects underwent a detailed ophthalmologic examination, including gonioscopy. Anterior segments of all subjects were evaluated with the Scheimpflug system and pupil diameter (PD), central corneal thickness, anterior chamber depth (ACD), anterior chamber volume, and anterior chamber angle (ACA) measurements were enrolled. Results: The median IOP was significantly lower in patients using antidepressants [16.0 (11.0–21.0) mmHg] than the control group [17.5 (12.0–21.0) mmHg] (P = 0.041). The PD was significantly larger in patients using antidepressants [3.56 (2.29–5.60) mm] than the control group [2.95 (2.00–4.40) mm] (P = 0.000). In the study group, PD was also significantly larger in patients using SNRIs for ≥6 months [3.67 (2.38–5.08) mm] than <6 months [3.31 (2.29–5.60) mm] (P = 0.000). The median ACD was significantly lower in patients using antidepressants for ≥6 months [3.21 (2.52–4.06) mm] than the control group [3.44 (2.63–4.29) mm] (P = 0.000). ACAs were measured between 25° and 55° by Scheimpflug imaging. Conclusions: Treatment of SNRIs causes mydriasis and decrease in width of ACD. These changes may not increase IOP as long as the patient has an open angle. SNRIs lead to decrease in IOP particularly in long-term usage.
Purpose: This study aims to evaluate the nonpharmacological safety profile of intravitreal dexamethasone implants in cases with different etiologies. Methods: This retrospective university-based study analyzed clinical reports of patients receiving 0.7 mg dexamethasone implant injections between 2013 and 2023. The study recorded patient demographics, injection indications, and follow-up data. Complications caused by the injection procedure and adverse events other than pharmacological side effects within a 3-month period were included. Results: In this study, 3,430 dexamethasone implant injections were made into 1,471 eyes of 1,091 patients. Nonpharmacological complications developed in 611 injections (17.8%). Subconjunctival hemorrhage was noted as the leading nonpharmacological complication (n = 576, 16.8%). Sight-threatening 35 nonpharmacological adverse events and complications (1.0%) were recorded. Cases of anterior chamber migration, vitreous hemorrhage, retinal detachment, endophthalmitis, hypotony, and implant misplacement were observed. Cases requiring intensive treatments and additional surgical interventions were encountered. Conclusion: The injection of the dexamethasone implant may lead to nonpharmacological complications caused by the mechanical impact of the injection or improper positioning of the implant, potentially resulting in vision loss. Severe outcomes such as corneal decompensation, retinal detachment, and endophthalmitis can ensue, emphasizing the gravity of these complications. Careful selection of patients and adherence to proper injection techniques are essential in reducing these risks.